Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

Hellmann D B. Immunopathogenesis, diagnosis, and treatment of giant cell arteritis, temporal arteritis, polymyalgia rheumatica, and Takayasu's arteritis. Curr Opin Rheumatol 1993; 5: 25-32.

Healey L A. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13: 322-8.

Bengtsson B-A, Malmvall B-E. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 1981; 209: 337-45.

Kyle V, Hazleman B L. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993; 52: 847-50.

Femandez-Herlihy L. Temporal arteritis: clinical aids to diagnosis. Rheumatol 1988; 15: 1797-801.

Behn A R, Perera T, Myles A B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374-8.

Fernandez-Herlihy L. Duration of corticosteroid therapy in giant cell arteritis. JRheumatol 1980; 7: 361-4.

Ayoub W T, Franklin C M, Toretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am JMed 1985; 79: 309-15.

Huston K A, Hunder G G. Giant cell (cranial) arteritis: a clinical review. Am HeartJ 1980; 100: 99-107.

Healey L A, Wilske K R. Treatment of resistant giant cell arteritis. Arthritis Rheum 1983; 26: 930.

Kyle V, Hazleman B L. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. Treatment usually lasts for two to five years. BMJt 1990; 300: 344-5.

Kyle V, Hazleman B L. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6.

Shiner R J, Nunn A J, Fan Chung K, Geddes D M. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336: 137-40.

Hoffman G S, Leavitt R Y, Kerr G S, Rottem M, Sneller M C, Fauci A S. Treatment of glucocorticoidresistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82.

Hemrndez-Garcia C, Soriano C, Morado C, et al. Methotrexate treatment in the management ofgiant cell arteritis. ScandJRheumatol 1994; 23: 295-8.

Hunder G G, Bloch D A, Michel B A, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.

Goldsmith C H, Smythe H A, Helewa A. Interpretation and power of a pooled index. J Rheumatol 1993; 20: 575-8.

Krall P L, Mazanec D J, Wilke W S. Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis. Cleve ClinJfMed 1989; 56: 253-7.

Bengtsson B-A, Malmvall B-E. The epidemiology ofgiant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 1981; 24: 899-904.

Myles A B, Perera T, Ridley M G. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992; 31: 103-5.

Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi J B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47: 733-9.